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Figure 1. Overall survival (OS) and event-free survival (EFS).
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Background: Allogeneic hematopoietic cell transplantation
(HCT) is the only treatment option able to prevent progressive
neurodegenerative disease in a selected group of mucopoly-
saccharidoses (MPS)disorders.However, itsusewashistorically
limited by the high risk of graft failure and HCT-related
morbidityandmortality. Therefore in2005, theEuropeanBlood
and Marrow Transplantation group developed transplantation
guidelines forHCT inMPS patients.Weprospectively evaluated
the outcomes of HCT in MPS patients, complying with these
international guidelines in two centers performing the highest
numbers of HCT in MPS patients in Europe.
Methods: Two consecutive conditioning regimens were
used, either Busulfan/Cyclophosphamide (Bu/Cy) or Fludar-
abine/Busulfan (Flu/Bu)-based, both with exposure-targeted
intravenous Busulfan. A non-carrier matched sibling donor
(MSD) or an identical unrelated cord blood (UCB, 6/6 on in-
termediate resolution) or identical matched unrelated donor
(MUD, 10/10 on high-resolution typing) were considered
preferred donors. If not available, a mismatched UCB donor
was used.
Results: 62 MPS patients were included (56 MPS type I e
Hurler, 2 MPS type II, 2 MPS type III, and 2 MPS type VI); 29
receiving a BuCy, 33 a FluBu-based conditioning regimen.
Median age at HCTwas 13.5 (range 3-44) months. 41 patients
received an UCB donor, 17 a MSD, and 4 a MUD. High overall
survival (95.2%) and event-free survival (90.3%) were ach-
ieved (Figure 1). All three patients with graft failure received
a second HCT and are alive and with successful donor
engraftment at latest follow-up. A mismatched donor
predicted for lower event-free survival (p¼0.04). The
probability of aGVHD grade II-IV was 13.3%, while 14.8% of
the patients were diagnosed with cGVHD (1.9% extensive).
A higher age at HCT was a predictor for both aGVHD
(p¼0.001) and cGVHD (p¼0.01). The use of a mismatched
donor was a predictor for aGVHD (p¼0.01). Full-donor
chimerism and normal enzyme levels were found in 88.2%
and 95.1% of the patients, respectively. Higher rates of full-
donor chimerismwere achieved in UCB recipients (p¼0.002).
Conclusion: If complying with the international HCT
guidelines, HCT in MPS patients results in high safety and
efﬁcacy. This allows extension of HCT to more attenuated
MPS types such as MPS type I e Hurler-Scheie. As a younger
age at HCT is associated with reduction of HCT-related
toxicity, newborn screening may further increase safety.90
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Background: The combination of Clofarabine + Fludarabine
+ Busulfan (CloFluBu) was found to have synergistic anti-
leukemic activity against ALL and AML blasts in vitro
(Andersson et al: BBMT 2011). As TBI induces signiﬁcant late
effects in childhood ALL, and AML patients have high relapse
rates, we hypothesized that CloFluBu may be an interesting
alternative to TBI in ALL and add anti-leukemic activity in
AML. Within the “Dutch COG HCT Working Group” we pro-
spectively studied the outcomes of CloFluBu-conditioning
regimen for lymphoblastic and myeloid malignancies.
Methods: Patients from the 2 pediatric HCT programs (LUMC
and UMC Utrecht) with a lymphoblastic or myeloid malig-
nancy were included from Aug-2011 to present. Clofarabine
30mg/m2 was given in 1 hour, followed by Fludarabine
10mg/m2 in 1 hour followed by a 3-hour infusion of once
daily targeted busulfan (weight-based dosing: with thera-
peutic drug monitoring). Thymoglobulin was added in un-
related donors (except in AML patients receiving cord blood:
CB) and GvHD prophylaxis was according to standard pro-
tocols. The cumulative target area under the curve (AUC) for
Bu was 90 mg*h/L. Primary endpoint: leukemia free survival
(LFS) and overall survival (OS). Other endpoints: acute and
chronic graft-versus-host disease (GvHD), VOD, non-infec-
tious lung injury, neutrophil (@day60) and thrombocyte
engraftment (@day 180). A predictor analysis was performed
using Cox Proportional Hazard Models.
Results: 62 patients were included: 28 AML-CR2,14 ALL-CR1,
3 Infant-ALL, 11 ALL-CR2/3, 6 other (4 MDS, 2 CML, 1CNL).
10/19 ALL-CR1-3 patients with available MRD status prior to
HCT were positive: 4 >10e-3 and 6 < 10e-3. Donors used: 25
unrelated CB, 14 (matched) Family donors (FD; 1 Haplo-
identical) and 23 Matched Unrelated Donors. Median age at
HCT: 10.9 (0.5-17.9) years. Median follow-up 298 (range
18-1182) days. The estimated 2-year OS/LFS was 74+/-7%
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estimated NRM@1year of 9+/-4% and relapse@1year of 21+/-
7%. Other endpoints: Probability of neutrophil engraftment
100% @day60 and thrombocyte engraftment (50x10e9/L) of
84+/-6% @day 180, only 1 graft failure (1.5%: MUD donor.
Successfully re-grafted with CB) was noted. Toxicity end-
points: aGvHD 2-4 @day 180 was 32+/-6% (grade 3-4: 14+-
4%), extensive cGvHD@1year 8+-6%, non-infectious lung-
injury @ 2 years 12+-4% and no VOD (0%) was noted.
Conclusion: The preliminary results of this TBI-free condi-
tioning regimen (CloFluBu) in myeloid- and lymphoblastic
malignancies showed limited toxicity and encouraging LFS
given the high risk group of patients. A longer follow-up and
a larger cohort is needed to draw ﬁrm conclusions with
regards to the anti-leukemic effect and late effects.Figure 1. Overall survival (OS) and event-free survival (EFS).91
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Fanconi anemia(FA) is a rare genetic disorder characterizedby
congenital defects, bone marrow failure and cancer predis-
position. Over the past decade, survival after HSCT has greatly
improved and the use of protocols without radiation are
preferred in order to decrease late complications related to
the development of head and neck cancer. In this study we
analyzed 103 patients(pts) with FA who were transplanted
between 2003 and 2014. The median age at HSCT was
9ys(range: 3-23ys). All pts were transplanted in marrow
failure and received bone marrow from matched siblings
(MSD) (n¼49) or Alternative donors (AD) (n¼54). This latter
group included 12 other related donors(ORD) and 42 unre-
lated donors(URD). Preparatory regimen with Cyclophos-
phamide 60mg/kg(CY60) was given to all pts with MSD or
ORDwhile ptswith URD received CY60 + Fludarabine 125mg/
m2 + rabbit ATG 5mg/kg. All pts received GVHD prophylaxis
with cyclosporine and methotrexate. Three pts died before
D+28 andwerenot evaluable for engraftment (MSD: 2 pts and
URD: 1 pt). One patient (MSD) developed primary graft fail-
ure, received a 2nd transplant without success andwas ﬁnally
rescued after a 3rd transplantwith a haploidentical donor. She
is alive andwell 3ys after HSCT. Ninety-nine pts engrafted but
5 pts developed late graft failure (MSD¼2pts; ORD¼1pt;
URD¼1pt) between 50 and 742 days after transplant (M: 84
days). Four out of these 5 pts are alive andwell with full donor
chimerism after a 2nd or 3rd HSCT. At last follow-up, the ma-
jority of pts transplanted from AD had full donor chimerism
(96%) while approximately 50% of pts with MSD donors had
mixed chimerism.Mucositis grade II-III occurred in 70%of pts.
Viral infectionsweremore frequentwhenADwereused(60%)
compared toMSD(28%). Hemorrhagic cystitis occurred in 22%
of AD transplants and it was uncommon after MSD trans-
plants (only1 pt). After AD transplantation, acuteGVHDgradeII-IV occurred in 12/53 evaluable pts and any Chronic GVHD
occurred in 21/38 evaluable pts.MSDhad a lower incidence of
acute GVHD (3/47 evaluable pts) while Chronic GVHD
occurred in 14/47 evaluable pts. Ninety-one pts are alive be-
tween 7 months and 10 years (M: 5 yrs) with an overall sur-
vival of 87% at 5 years. There was no difference in survival
according to the type of donor MSD (92%), ORD (92%) and
URD(83%). Patients without Acute GVHD had an overall sur-
vival of 98% compared to 58% with acute GVHD (p:0.001).
Twelve pts died between 3 and 1855 days after HSCT(M:65
days). Acute or chronic GVHDwere the major causes of death
(n¼8) followed by infections (n¼3) and central nervous sys-
tem bleeding (n¼1).
Conclusions: HSCT for FA has improved dramatically during
the past decade. In this study, the use of non-irradiation
protocols was associated with an excellent survival, suc-
cessful engraftment and very low mortality rate.
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Background: Cord blood transplant (CBT) recipients have
delayed hematopoietic recovery compared to recipients of
other stem cell sources following allogeneic transplant. Pro-
longed neutrophil (ANC) recovery, in particular, places these
patients at risk of protracted mucositis, extended hospitali-
zation and increased risk of infection-related morbidity and
mortality. To mitigate these risks, we have developed a
methodology for generating increased absolute numbers of
cord blood (CB) hematopoietic stem/progenitor cells (HSPC)
by culture of the CB HSPC in the presence of Notch ligand,
cryopreserving theﬁnal harvested product, and subsequently
administering the product as an adjunct cellular therapy to
patients receiving CBT. This has resulted in signiﬁcantly
decreased time to neutrophil recovery following CBT1. Here
we evaluatedwhether administration of these cells impacted
duration of hospitalization, use of opiate pain medications,
and requirement for total parenteral nutrition (TPN) or in-
fectious outcomes during initial hospitalization for CBT.
